Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
Advantages of multi-arm non-randomised sequentially allocated cohort designs for Phase II oncology trials.
复制标题
DOI:
10.1038/s41416-021-01613-5
复制
发表时间:
2022-03
影响因子:
8.8
通讯作者:
Wason JMS
中科院分区:
文献类型:
--
作者:
Mossop H;Grayling MJ;Gallagher FA;Welsh SJ;Stewart GD;Wason JMS
Efficient trial designs are required to prioritise promising drugs within Phase II trials. Adaptive designs are examples of such designs, but their efficiency is reduced if there is a delay in assessing patient responses to treatment. Motivated by the WIRE trial in renal cell carcinoma (NCT03741426), we compare three trial approaches to testing multiple treatment arms: (1) single-arm trials in sequence with interim analyses; (2) a parallel multi-arm multi-stage trial and (3) the design used in WIRE, which we call the Multi-Arm Sequential Trial with Efficient Recruitment (MASTER) design. The MASTER design recruits patients to one arm at a time, pausing recruitment to an arm when it has recruited the required number for an interim analysis. We conduct a simulation study to compare how long the three different trial designs take to evaluate a number of new treatment arms. The parallel multi-arm multi-stage and the MASTER design are much more efficient than separate trials. The MASTER design provides extra efficiency when there is endpoint delay, or recruitment is very quick. We recommend the MASTER design as an efficient way of testing multiple promising cancer treatments in non-comparative Phase II trials.
登录
查看更多内容
影响因子:
8.4
作者:
Wason, James M. S.;Mander, Adrian P.;Eisen, Tim G.
通讯作者:
Eisen, Tim G.
影响因子:
2.3
作者:
Wason, James M. S.;Jaki, Thomas
通讯作者:
Jaki, Thomas
影响因子:
4
作者:
Yap C;Pettitt A;Billingham L
通讯作者:
Billingham L
DOI:
10.1111/j.1467-9868.2012.01030.x
发表时间:
2013-01-01
影响因子:
5.8
作者:
Hampson, Lisa V.;Jennison, Christopher
通讯作者:
Jennison, Christopher
影响因子:
4.7
作者:
Maria del Campo, Josep;Birrer, Michael;Oza, Amit
通讯作者:
Oza, Amit